Qualigen Therapeutics Inc Stock

$3.44

3.64% yesterday

Nasdaq, Jun 25, 10:00 pm CET

ISIN

US74754R1032

Symbol

QLGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Qualigen Therapeutics Inc Stock price

$3.44

-2,346.56 99.85% 5Y

Nasdaq, Closing price Wed, Jun 25 2025

-0.13 3.64%

ISIN

US74754R1032

Symbol

QLGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$2.6m

Enterprise Value

$3.7m

Net debt

$1.1m

Cash

$390.0k

Shares outstanding

550.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-103.46%

Return on Equity

637.82%

ROCE

313.32%

ROIC

1,264.07%

Debt/Equity

-0.67

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | -

EBIT

$-6.7m

Net Income

$-7.9m | $-5.1m

Free Cash Flow

$-9.7m

Growth (TTM | estimate)

Revenue

-100.00% | -

EBITDA

- | -

EBIT

53.53%

Net Income

54.21% | 62.37%

Free Cash Flow

-41.63%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-20.47

FCF per Share

$-17.69

Short interest

4.02%

Employees

4.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Qualigen Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Qualigen Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Qualigen Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Qualigen Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.15 4.15	54% 54% -
- Research and Development Expense	2.55 2.55	62% 62% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-6.71 -6.71	54% 54% -
Net Profit	-7.94 -7.94	54% 54% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Qualigen Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company's failu...

Neutral

GlobeNewsWire

●

about 2 months ago

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the...

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

Head office	United States
CEO	Kevin Richardson
Employees	4
Founded	2004
Website	qlgntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now